Siponimod-associated cystoid macular edema without known risk factors
American Journal of Ophthalmology Case ReportsPurpose: This case report highlights the importance of monitoring ocular health for patients starting on siponimod treatment, a sphingosine-1-phosphate receptor modulator, for relapsing-remitting multiple sclerosis.
Min Young Kim +3 more
doaj +2 more sources
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date [PDF]
Drug Design, Development and Therapy, 2017 Alberto Gajofatto Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy Abstract: Siponimod (BAF312) is a synthetic molecule belonging to the sphingosine-1-phosphate (S1P) modulator family, which has ...
Gajofatto A
doaj +2 more sources
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021 Background Siponimod (BAF312), a selective S1P 1 /S1P 5 agonist, reduces disability progression in secondary progressive MS. Recent observations suggest it could act via S1P 1 /S1P 5 -dependent anti-inflammatory and pro-myelination effects on CNS ...
Marc Bigaud +8 more
doaj +2 more sources
Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
Neurology and Therapy, 2023 Introduction Siponimod, a potent and selective sphingosine-1-phosphate (S1P1,5) agonist, is the only therapeutic agent that has shown efficacy against disability progression, decline in cognitive processing speed, total brain volume loss, gray matter ...
Marc Bigaud +6 more
doaj +2 more sources
Effects of sphingosine-1-phosphate receptor modulators on remyelination in multiple sclerosis: evidence from in vitro experiments, animal models and human studies [PDF]
Frontiers in ImmunologySphingosine-1-phosphate (S1P) receptor modulators are a class of therapeutic agents used for the treatment of multiple sclerosis (MS). There are four S1P modulators currently approved by the Food and Drug Administration/European Medical Agency (FDA/EMA):
Vito A.G. Ricigliano +1 more
doaj +2 more sources
Siponimod for relapsing-remitting multiple sclerosis: a single-center, real-world cohort study in China [PDF]
BMC NeurologyBackground Siponimod is a new-generation sphingosine-1-phosphate (S1P) receptor modulator that has demonstrated efficacy and tolerability in patients with secondary progressive multiple sclerosis (SPMS) in pivotal trial.
Hongmei Tan +7 more
doaj +2 more sources
Siponimod supports remyelination in the non-supportive environment [PDF]
Scientific ReportsInflammatory demyelination, a hallmark of multiple sclerosis (MS) lesions, leads to functional impairments and progressive axonal loss over time. Although remyelination is thought to protect axons, endogenous regenerative processes are often incomplete ...
Johann Krüger +6 more
doaj +2 more sources
Patient Preference and Adherence, 2022 Sajida Sabsabi,1 Elio Mikhael,2 Georges Jalkh,1 Gabrielle Macaron,1,3 Mary Rensel3 1Department of Neurology, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon; 2Department of Internal Medicine, Hotel Dieu de France Hospital, Saint ...
Mary Rensel +2 more
exaly +2 more sources
Fungal Infections Associated with Sphingosine 1-Phosphate Receptor Modulators: Immunological Mechanisms, Clinical Patterns, and Management Considerations [PDF]
MicroorganismsFungal infections constitute a large portion of serious infections worldwide and are increasing, partially due to new immunomodulatory therapies, such as Sphingosine-1-Phosphate (S1P) receptor modulators, including fingolimod for the treatment of ...
Kian Michael Yazdan +2 more
doaj +2 more sources
Siponimod treatment response shows partial BDNF dependency in multiple sclerosis models
Scientific ReportsSo far, only a small number of medications are effective in progressive multiple sclerosis (MS). The sphingosine-1-phosphate-receptor (S1PR)-1,5 modulator siponimod, licensed for progressive MS, is acting both on peripheral immune cells and in the ...
Hasan Hüseyin Hendek +7 more
doaj +4 more sources